Zydus Lifesciences Limited (NSE:ZYDUSLIFE)
901.85
+17.00 (1.92%)
May 13, 2025, 3:29 PM IST
Zydus Lifesciences Revenue
Zydus Lifesciences had revenue of 52.69B INR in the quarter ending December 31, 2024, with 16.96% growth. This brings the company's revenue in the last twelve months to 222.47B, up 16.94% year-over-year. In the fiscal year ending March 31, 2024, Zydus Lifesciences had annual revenue of 195.47B with 13.40% growth.
Revenue (ttm)
222.47B
Revenue Growth
+16.94%
P/S Ratio
4.08
Revenue / Employee
8.26M
Employees
26,921
Market Cap
907.47B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 195.47B | 23.10B | 13.40% |
Mar 31, 2023 | 172.37B | 21.28B | 14.08% |
Mar 31, 2022 | 151.10B | 7.06B | 4.90% |
Mar 31, 2021 | 144.04B | 1.50B | 1.06% |
Mar 31, 2020 | 142.53B | 10.88B | 8.26% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 516.03B |
Divi's Laboratories | 90.78B |
Cipla | 267.20B |
Mankind Pharma | 116.41B |
Apollo Hospitals Enterprise | 211.46B |
Aurobindo Pharma | 309.22B |
Alkem Laboratories | 127.57B |
Fortis Healthcare | 75.61B |
Zydus Lifesciences News
- 4 days ago - Zydus gets USFDA nod for generic version of Copaxone for treatment of Multiple Sclerosis - Business Upturn
- 13 days ago - Zydus gets USFDA final approval for Niacin Extended-Release Tablets - Business Upturn
- 15 days ago - Stocks to watch on April 28: Force Motors, Jayaswal Neco, NRB Bearings, Titan, Reliance Industries, Zydus Lifesciences in focus - Business Upturn
- 17 days ago - Zydus Lifesciences receives 6 observations from USFDA for Gujarat API unit - The Times of India
- 17 days ago - Zydus Lifesciences receives 6 observations in USFDA inspection at API unit in Dabhasa, Gujarat - Business Upturn
- 26 days ago - Zydus Medtech, Braile Biomedica sign global licensing pact to commercialise advanced TAVI technology - Business Upturn
- 26 days ago - Zydus Lifesciences confirms losing US patent case to Astellas in mirabegron litigation - Business Upturn
- 26 days ago - Zydus Lifesciences shareholder commitments in tender offer for Amplitude Surgical - Business Upturn